A citation-based method for searching scientific literature

Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
Times Cited: 97







List of co-cited articles
708 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.
Lars Wichmann Madsen, Jeffrey A Knauf, Carsten Gotfredsen, Andrew Pilling, Ingrid Sjögren, Søren Andersen, Lene Andersen, Anne Sietske de Boer, Katia Manova, Afsar Barlas,[...]. Endocrinology 2012
76
5



Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Mark S Fineman, K F Mace, M Diamant, T Darsow, B B Cirincione, T K Booker Porter, L A Kinninger, M E Trautmann. Diabetes Obes Metab 2012
101
4


Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes.
Akira Shimada, Toshikatsu Shigihara, Yoshiaki Okubo, Takeshi Katsuki, Yoshifumi Yamada, Yoichi Oikawa. Diabetes Metab Res Rev 2011
10
40


Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
Michael W Steffes, Shalamar Sibley, Melissa Jackson, William Thomas. Diabetes Care 2003
445
4

The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
Iben Brock Jacobsen, Jan Erik Henriksen, Henning Beck-Nielsen. Basic Clin Pharmacol Toxicol 2009
35
11


Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes.
Ted Okerson, Ping Yan, Anthony Stonehouse, Robert Brodows. Am J Hypertens 2010
129
4

The safety of incretin-based therapies--review of the scientific evidence.
Daniel J Drucker, Steven I Sherman, Richard M Bergenstal, John B Buse. J Clin Endocrinol Metab 2011
128
4


Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
Bo Ahrén, Mona Landin-Olsson, Per-Anders Jansson, Maria Svensson, David Holmes, Anja Schweizer. J Clin Endocrinol Metab 2004
516
4



Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
909
4

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
Michael A Nauck, Markus M Heimesaat, Kai Behle, Jens J Holst, Markus S Nauck, Robert Ritzel, Michael Hüfner, Wolff H Schmiegel. J Clin Endocrinol Metab 2002
399
4


Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: The CACTI study.
Irene E Schauer, Janet K Snell-Bergeon, Bryan C Bergman, David M Maahs, Adam Kretowski, Robert H Eckel, Marian Rewers. Diabetes 2011
141
4

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Sten Madsbad, Thure Krarup, Carolyn F Deacon, Jens J Holst. Curr Opin Clin Nutr Metab Care 2008
77
5




Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
4

Hypoglycemia in diabetes.
Philip E Cryer, Stephen N Davis, Harry Shamoon. Diabetes Care 2003
732
4

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Lancet 2011
347
4

Early loss of the glucagon response to hypoglycemia in adolescents with type 1 diabetes.
Aris Siafarikas, Robert J Johnston, Max K Bulsara, Peter O'Leary, Timothy W Jones, Elizabeth A Davis. Diabetes Care 2012
61
6

Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Stuart A Weinzimer, Jennifer L Sherr, Eda Cengiz, Grace Kim, Jessica L Ruiz, Lori Carria, Gayane Voskanyan, Anirban Roy, William V Tamborlane. Diabetes Care 2012
86
4

AMP-activated protein kinase: Role in metabolism and therapeutic implications.
Greg Schimmack, Ralph A Defronzo, Nicolas Musi. Diabetes Obes Metab 2006
94
4




Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Michael A Nauck, Guido Kemmeries, Jens J Holst, Juris J Meier. Diabetes 2011
205
4

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.
Aaron S Kelly, Kyle D Rudser, Brandon M Nathan, Claudia K Fox, Andrea M Metzig, Brandon J Coombes, Angela K Fitch, Eric M Bomberg, M Jennifer Abuzzahab. JAMA Pediatr 2013
89
4

Glucagon-like peptide 1(GLP-1) in biology and pathology.
Juris J Meier, Michael A Nauck. Diabetes Metab Res Rev 2005
195
4


Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study.
Kristen J Nadeau, Kelsey Chow, Suhyla Alam, Kara Lindquist, Sarah Campbell, Kim McFann, Georgeanna Klingensmith, Phillipe Walravens. Pediatr Diabetes 2015
46
8

Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Keith C Ferdinand, William B White, David A Calhoun, Eva M Lonn, Philip T Sager, Rocco Brunelle, Honghua H Jiang, Rebecca J Threlkeld, Kenneth E Robertson, Mary Jane Geiger. Hypertension 2014
82
4


Glycemic control and excess mortality in type 1 diabetes.
Marcus Lind, Ann-Marie Svensson, Mikhail Kosiborod, Soffia Gudbjörnsdottir, Aldina Pivodic, Hans Wedel, Sofia Dahlqvist, Mark Clements, Annika Rosengren. N Engl J Med 2014
422
4

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Michael J Theodorakis, Olga Carlson, Spyros Michopoulos, Máire E Doyle, Magdalena Juhaszova, Kalliopi Petraki, Josephine M Egan. Am J Physiol Endocrinol Metab 2006
252
4


Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
David G Marrero, John Crean, Bei Zhang, Terrie Kellmeyer, Maurice Gloster, Kathrin Herrmann, Richard Rubin, Naomi Fineberg, Orville Kolterman. Diabetes Care 2007
32
12

Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.
J E Schopman, J B L Hoekstra, B M Frier, M T Ackermans, J J J de Sonnaville, A M Stades, R Zwertbroek, B Hartmann, J J Holst, F K Knop,[...]. Diabetes Obes Metab 2015
13
30

Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
682
4


Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
Christian S Frandsen, Thomas F Dejgaard, Henrik U Andersen, Jens J Holst, Bolette Hartmann, Birger Thorsteinsson, Sten Madsbad. Diabetes Obes Metab 2017
14
28

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
Julia K Mader, Lene Jensen, Steen H Ingwersen, Erik Christiansen, Simon Heller, Thomas R Pieber. Clin Pharmacokinet 2016
6
66


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.